Chronic Urticaria Market Report and Forecast 2024-2032

Chronic Urticaria Market Outlook

The chronic urticaria market size is expected to grow at a CAGR of 8.7% during the forecast period of 2024-2032, driven by the rising development of novel drugs to mitigate the incidence of chronic urticaria across the globe.

Chronic Urticaria: Introduction

Urticaria, commonly known as hives, is the presence of itchy, red bumps (welts) on the skin. These welts can be small, ring shaped, or irregularly shaped structures. If they persist for six weeks or longer, it can be declared as chronic urticaria. Although it is not life threatening, chronic urticaria can be a symptom of health issues like type 1 diabetes, lupus, rheumatoid arthritis, an autoimmune disorder, or celiac disease.

Urticaria is generally caused by an allergic reaction. It can be caused by allergens like pollen, food, medications, animal dander, or insect bites. People with high stress, illnesses, and other infections might also suffer from it. The body starts releasing histamines in the blood when it goes through an allergic reaction. Histamines can cause swelling and itching, among other symptoms. It is mostly treated with the help of antihistamines, antidepressants, monoclonal antibodies, and H2 blockers.

Chronic Urticaria Market Analysis

Urticaria is triggered by histamine release in the body. They are produced when the body attempts to fight against a foreign intruder or infection. Certain type of drugs, including antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs), can also trigger the condition.

In addition, the prevalence of food preservatives, alcohol or tobacco consumption in modern lifestyle have also contributed to high urticaria cases. As the prevalence of the condition continues to grow, it will also lead to chronic urticaria market growth in the upcoming years.

Chronic urticaria is a prevalent disorder affecting at least 1%  of the world population, mostly young and middle-aged women. There are two types of chronic urticaria, chronic spontaneous urticaria and chronic inducible urticaria. Out of the two, chronic spontaneous urticaria accounts for approximately 50-75 % of the total cases. It is a complex disorder that is not triggered by environmental and physical factors. With high incidence, its treatment is key area interest in scientists.

Several drugs for chronic spontaneous urticaria are under clinical trials with results awaited in 2024. Amgen’s tezepelumab, Allakos’s lirentelimab, and Celldex Therapeutics’s barzolvolimab are some of the most prominent ones. Sanofi and Regeneron are working on urticaria triggered by low temperature called Dupilumab. The drug is currently under Phase III trial with results expected to be out in 2024. The chronic urticaria market value is anticipated to rise in the coming years considering the upcoming drug approvals that can be extremely worthy to decrease the severity of the illness.

Chronic Urticaria Market Segmentation

Market Breakup by Therapeutic Class

• Antihistamines

• H-2 Blockers

• Antidepressants

• Monoclonal Antibodies

• Others

Market Breakup by Route of Administration

• Oral

• Parenteral

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Online Pharmacy

• Retail Pharmacy

• Others

Market Breakup by Region-7MM 

• United States

• EU-4 and the United Kingdom

• Japan

Chronic Urticaria Market Overview

More than 500,000  people in the United States alone are estimated to chronic urticaria. Therefore, majority of the chronic urticaria market share has been dominated by the North American region in the historical period. On contrary, as per recent trends, the North American region has lowest prevalence of the disease. This can be attributed to the existence of an effective healthcare and pharmaceutical system that leaps in innovation and scientific development to mitigate the disease.

Chronic urticaria market size is expected to grow further in the Latin American and Asian region, owing to high prevalence of cases in the future. The chances of women getting affected is greater than men, whereas for children below 15 years of age, there is not much gender associated difference. With the influx of government grants and foreign investments along with high-end technical advancements, the market can grow considerably in the coming years.

Chronic Urticaria Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Johnson & Johnson Private Limited

• Novartis AG

• Amneal Pharmaceuticals, Inc.

• Pfizer Inc.

• Mylan N.V

• GlaxoSmithKline plc

• Merck & Co., Inc.

Key Highlights of the Report